Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Volkmann

Showing results (141-150 of 198) with videos related to

Pageof 20
Sort By:
Seminars in Arthritis and Rheumatism|March 4, 2023
Gastrointestinal tract involvement in systemic sclerosis: The roles of diet and the microbiomeAudrey D Nguyen, Kristofer Andréasson, Zsuzsanna H McMahan, et al.
Journal of Endodontics|February 27, 2007
Efficacy of two contemporary single-cone filling techniques in preventing bacterial leakageFrancesca Monticelli, Fernanda T Sadek, George S Schuster, et al.
Arthritis Research & Therapy|January 18, 2019
Minimal Clinically Important Differences for the Modified Rodnan Skin Score: Results from the Scleroderma Lung Studies (SLS-I and SLS-II)Dinesh Khanna, Philip J Clements, Elizabeth R Volkmann, et al.
ACR Open Rheumatology|February 17, 2022
Disease Features and Gastrointestinal Microbial Composition in Patients with Systemic Sclerosis from Two Independent CohortsKristofer Andréasson, S Melanie Lee, Venu Lagishetty, et al.
European Medical Journal (Chelmsford, England)|January 30, 2023
Longitudinal Characterisation of the Gastrointestinal Tract Microbiome in Systemic SclerosisElizabeth R Volkmann, Anna-Maria Hoffmann-Vold, Yu-Ling Chang, et al.
European Respiratory Review : an Official Journal of the European Respiratory Society|July 15, 2024
Lysophosphatidic acid receptor 1 inhibition: a potential treatment target for pulmonary fibrosisElizabeth R Volkmann, Christopher P Denton, Martin Kolb, et al.
Arthritis Research & Therapy|September 4, 2023
Anti-Ro52 positivity is associated with progressive interstitial lung disease in systemic sclerosis-an exploratory studyViggo Hamberg, Azita Sohrabian, Elizabeth R Volkmann, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|November 3, 2020
Effect of Nintedanib on Lung Function in Patients With Systemic Sclerosis-Associated Interstitial Lung Disease: Further Analyses of a Randomized, Double-Blind, Placebo-Controlled TrialToby M Maher, Maureen D Mayes, Michael Kreuter, et al.
The Lancet. Rheumatology|January 24, 2024
Safety and tolerability of nintedanib in patients with interstitial lung diseases in subgroups by sex: a post-hoc analysis of pooled data from four randomised controlled trialsAnna-Maria Hoffmann-Vold, Elizabeth R Volkmann, Yannick Allanore, et al.
Ebiomedicine|November 17, 2019
Endotype-phenotyping may predict a treatment response in progressive fibrosing interstitial lung diseaseAnna-Maria Hoffmann-Vold, S Samuel Weigt, Rajan Saggar, et al.
Pageof 20

Showing results (141-150 of 198) with videos related to

Sort By:
Pageof 20
Seminars in Arthritis and Rheumatism|March 4, 2023
Gastrointestinal tract involvement in systemic sclerosis: The roles of diet and the microbiomeAudrey D Nguyen, Kristofer Andréasson, Zsuzsanna H McMahan, et al.
Journal of Endodontics|February 27, 2007
Efficacy of two contemporary single-cone filling techniques in preventing bacterial leakageFrancesca Monticelli, Fernanda T Sadek, George S Schuster, et al.
Arthritis Research & Therapy|January 18, 2019
Minimal Clinically Important Differences for the Modified Rodnan Skin Score: Results from the Scleroderma Lung Studies (SLS-I and SLS-II)Dinesh Khanna, Philip J Clements, Elizabeth R Volkmann, et al.
ACR Open Rheumatology|February 17, 2022
Disease Features and Gastrointestinal Microbial Composition in Patients with Systemic Sclerosis from Two Independent CohortsKristofer Andréasson, S Melanie Lee, Venu Lagishetty, et al.
European Medical Journal (Chelmsford, England)|January 30, 2023
Longitudinal Characterisation of the Gastrointestinal Tract Microbiome in Systemic SclerosisElizabeth R Volkmann, Anna-Maria Hoffmann-Vold, Yu-Ling Chang, et al.
European Respiratory Review : an Official Journal of the European Respiratory Society|July 15, 2024
Lysophosphatidic acid receptor 1 inhibition: a potential treatment target for pulmonary fibrosisElizabeth R Volkmann, Christopher P Denton, Martin Kolb, et al.
Arthritis Research & Therapy|September 4, 2023
Anti-Ro52 positivity is associated with progressive interstitial lung disease in systemic sclerosis-an exploratory studyViggo Hamberg, Azita Sohrabian, Elizabeth R Volkmann, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|November 3, 2020
Effect of Nintedanib on Lung Function in Patients With Systemic Sclerosis-Associated Interstitial Lung Disease: Further Analyses of a Randomized, Double-Blind, Placebo-Controlled TrialToby M Maher, Maureen D Mayes, Michael Kreuter, et al.
The Lancet. Rheumatology|January 24, 2024
Safety and tolerability of nintedanib in patients with interstitial lung diseases in subgroups by sex: a post-hoc analysis of pooled data from four randomised controlled trialsAnna-Maria Hoffmann-Vold, Elizabeth R Volkmann, Yannick Allanore, et al.
Ebiomedicine|November 17, 2019
Endotype-phenotyping may predict a treatment response in progressive fibrosing interstitial lung diseaseAnna-Maria Hoffmann-Vold, S Samuel Weigt, Rajan Saggar, et al.
Pageof 20